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Autoantibodies against oxidatively-modified LDL in uremic patients
undergoing dialysis. Target-specific oxidation processes in LDL generate
molecular epitopes that are more atherogenic than the native forms and
are able to elicit an immunological reaction leading to the formation of
anti-oxLDL autoantibodies (0xLDL-Ab) that may participate in the
overall process of atherogenesis. Thus, the detection of oxLDLAb, in
addition to mirroring the occurrence of in vivo LDL oxidation, will give
valuable information on the occurrence of this immune response. Plasma
oxLDLAb (IgG and 1gM) were measured in 72 control subjects (CS) and
in 80 patients with chronic renal failure (CRF), undergoing repetitive
hemodialysis (N = 56) or peritoneal dialysis (N = 24), with an ELISA
method using native LDL, CuSO4-oxidized LDL (0xLDL) or malondial-
dehyde-derivatized LDL (MDA-LDL) as antigens. To monitor cross
reactivity of the antibodies detected with other oxidatively-modified
proteins, human serum albumin (HSA) and MDA-derivatized HSA
(MDA-HSA) were also employed as antigens. The antibody titer was
calculated as the ratio of antibodies against modified versus native
proteins. CRF patients had an antibody ratio significantly higher than CS
as concerning anti-oxLDL IgG (1.39 0.36 vs. 1.05 0.3, P < 0.05) and
1gM (2.15 0.75 vs. 1.43 0.43, P < 0.01), and anti-MDA-LDL IgG (3.05
0.74 vs. 2.04 0.42,P < 0.01) and 1gM (5.55 1.79 vs. 2.9 0.85, P
< 0.01). The anti-MDA-HSA antibody titer was also higher in CRF
patients than in CS (2.49 0.5 vs. 1.46 0.39, P < 0.01 for IgG and 2.80
1.03 vs. 1.26 0.43, P < 0.01 for 1gM). Subclass analysis regarding the
type of dialytic treatment revealed that the autoantibody pattern did not
differ between CRF patients on hemodialysis and peritoneal dialysis.
However, the ratio between anti-MDA-LDL and anti-MDA-HSA (a
parameter indicating the specificity of LDL over albumin as the molecule
triggering the immunological response) was higher in CRF patients on
hemodialysis as compared to peritoneal dialysis (1.34 0,43 vs.
1.12 0.29, P <0.05 for IgG and 2.41 1.22 vs. 1.75 0.78, P < 0.01 for
1gM). Furthermore, 10% of CRF patients had detectable levels of immune
complexes containing oxidized LDL and IgG. These data indicate that
CRF patients on dialytic treatment, and particularly on hemodialysis,
develop autoantibodies against oxidatively-modified LDL and support the
occurrence of an enhanced LDL oxidation in vivo.
Atherosclerosis is a multifactorial disease in which multiple
cellular and humoral factors are involved [1]. Growing evidence
has been obtained indicating that immune reactions, including
activation of T lymphocytes [2], aberrant expression of major
histocompatibility complex class II antigen by endothelial and
smooth muscle cells [3] and immune complex deposition [4], take
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place during the development and progression of the atheroscle-
rotic lesions. The pathogenetic relevance of these reactions has
been validated, for example, by the demonstration that athero-
sclerotic lesions can be induced in normocholesterolemic rabbits
by immunization with heat shock protein 65, a stress protein
expressed in high concentration in human atherosclerotic plaques
[5]. Moreover, high titers of anti-HSP65 autoantibodies have been
detected in patients with carotid atherosclerosis [6].
In a comparable group of patients, Salonen et al [7] have
reported that the presence of autoantibodies against LDL den-
vatized with malondialdehyde (MDA), a product of lipid peroxi-
dation, correlated with the progression of the atherosclerotic
disease. These findings were subsequently confirmed by our group
in patients undergoing aortocoronary bypass surgery for overt
coronary atherosclerosis [81 and in hypertensive patients [9]. All
these data prove that antigenic epitopes are generated by oxida-
tive modifications of LDL occurring in vivo.
LDL oxidation has been claimed to play a fundamental role in
the formation of early atherosclerotic lesions and in their progres-
sion [10]. Endothelial and smooth muscle cells as well as mono-
cytes and macrophages are able to trigger the peroxidation of
LDL lipids in the subendothelial space leading to the derivatiza-
tion of the apo B100 molecule with aldehydic products such as
MDA and HNE [11]. Oxidative modifications of LDL generate
molecular epitopes that provide chemotactic stimuli for monocyte
recruitment [12] are more avidly taken up by macrophages, thus
forming foam cells [13], and are cytotoxic for endothelial cells
[14]. Oxidized lipoproteins (0xLDL) are more atherogenic than
their parent forms, and the demonstration that LDL oxidation
does actually occur in vivo has promoted clinical investigations to
ascertain the role played by this process in the progression of
atherosclerosis in humans.
Patients with chronic renal failure on dialytic treatment often
develop moderate hyperlipidemia and accelerated atherosclero-
sis, and more than 50% of them die from cardiovascular compli-
cations [15, 16]. We have recently reported that LDL isolated
from uremic patients are more susceptible to in vitro oxidation as
compared to LDL from healthy subjects and that an enhanced
LDL oxidation does actually takes place in vivo [17]. The possi-
bility that an oxidant injury might be implicated in some processes
involved in the pathogenesis of atherosclerosis among CRF
patients on dialysis was indirectly supported by previous investi-
gations reporting an increased lipid peroxidation [18] and a low
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Table 1. Clinical and demographic parameters of the CRF patients
under study
Parameters
Total uremic
patients(N = 80)
Patients on
hemodialysis(N = 56)
Patients on
peritoneal dialysis(N = 24)
Age years 60.7 14.3 61.5 13.6 58.9 16.1
Sex 40 F, 40 M 26 F, 30 M 14 F, 10 M
BMI 24.8 4.8 23.5 3 26.9 5.1
Duration of dialytic 50.5 39.3 54.1 43.4 41.9 26.1
treatment months
Total cholesterol mg/dl 201 52.9 190.2 47.1 227 57
LDL cholesterol mgldl 118 46 109 40 140 52
HDL cholesterol mg/dl 43.1 14.3 43 15.3 43 11.8
Triglycerides mgldl 200 92.8 190 80 221 114
glutathione peroxidase activity and selenium concentration [19]
during hemodialysis.
In this work we investigated the presence of autoantibodies
against oxidatively-modified LDL and 0xLDL-containing immune
complexes in plasma of CRF patients on dialytic treatment, Data
are reported demonstrating the occurrence of an immune re-
sponse to oxLDL and MDA-modified LDL in uremic patients.
The detection of autoantibodies also against MDA-modified HSA
indicates that MDA-derivatization may represent the molecular
epitope involved, Moreover, the evaluation of the immune re-
sponse specificity for MDA-LDL over MDA-HSA suggests that
immune stimulation by oxLDL is more strictly associated with
hemodialysis as compared to peritoneal dialysis.
Methods
Patients
Eighty unselected uremic patients have been investigated: 56
were on repetitive hemodialysis, three times a week with an
HC03 dialysis using hemophane (N = 25), cuprophane (N =
10), polyacrylonitrile (N 19) and cellulose acetate (N = 2)
membranes, and 24 were on conventional CAPD treatment
(Table 1). They were compared with 72 control subjects matched
for age and sex. None of the control subjects had clinically-evident
signs of atherosclerotic diseases, hypertension, diabetes mellitus,
dislipidemia and renal failure, The majority of the patients
investigated (55%) had a post-inflammatory chronic renal failure
(glomerulonephritis, pyelonephritis, LES) (Table 2). Diabetes
mellitus was present in 12.5% and hypertension was present in
55% of the patients and was clinically well-controlled with con-
ventional hypoglycemic and anti-hypertensive therapy. The mean
duration of the dialytic treatment was 54.1 43.4 (range 6 to 190)
and 41.9 26.1 (range 7 to 110) months for CRF patients on
hemodialysis and peritoneal dialysis, respectively. The adequacy
of the dialytic treatment was evaluated using the KtIV (urea) [20]
that ranged from 1 to 1.2 for hemodialytic patients and from 1.6
to 1.8 (weekly) for CAPD patients. The Kt/V was calculated using
a commercially available computer program. Each patient was
scored on the basis of previous myocardial infarction(s), cerebral
transitory or persistent ischemic attack(s), symptomatic ischemic
cardiomyopathy and peripheral vasculopathies. From each patient
venous blood was taken before the first dialysis session of the
week after overnight fasting, in polypropylene tubes containing
K-EDTA (final concentration 1 mg EDTA!ml blood), and plasma
was collected after centrifugation and stored at —20°C until use.
Table 2. Primary reasons of renal diseases which led to dialytic
treatment
Diseases % Incidence
Polycistic renal disease 11.6
Nephroangiosclerosis 17.9
Chronic glomerulonephritis 15.6
MP glomerulonephritis 2.5
Focal glomerulonephritis 2.5
Membranous glomerulonephritis 1.3
SLE 1.3
Pyelonephritis 10.3
Nephrolithiasis 7.7
IgA nephropathy 2.5
Type I diabetes mellitus 6.4
Type IL diabetes mellitus 2.5
Toxic nephropathy 25
Uratic nephropathy 1.3
Obstructive or reflux nephropathy 3.7
Unspecified pathology 15.1
LDL preparation
Venous blood was taken from normal volunteers, after over-
night fasting, in polypropilene tubes containing K-EDTA (final
concentration 1 mg EDTA/ml blood), and plasma was collected
after centrifugation. The LDL fraction was isolated from the
whole plasma by ultracentrifugation through a KBr discontinuous
gradient and collected as the fraction floating at a density of 1.019
to 1.063 g/ml.
Antigen preparation
Non-modified LDL and human serum albumin. Native LDL,
obtained after plasma ultracentrifugation, were kept in saline
phosphate (10 mM) buffer, pH 7.2 containing EDTA (1 mg/mI)
and immediately used to coat ELISA plates. Human serum
albumin was purchased as a 20% solution (wt/vol) in saline
phosphate buffer from Pasteur Merieux SV and diluted in the
same buffer containing EDTA (1 mg/mI).
Oxidized LDL. EDTA was removed from the LDL fraction by
rapid filtration through disposable desalting columns Econo-Pac
10 DG (Bio-Rad) and LDL were resuspended in oxygen-saturated
phosphate-buffered saline (10 mvi Pi, pH 7.2) at a concentration
of 0.25 mg LDL mass/ml buffer (50 g LDL protein/mI =0.1 SM).
LDL oxidation was then triggered by the addition of 2 .LM CuSO4
and continuously monitored spectrophotometrically at 234 nm, to
follow the formation of conjugated dienes as described by Ester-
bauer et al [21]. After 18 hours the oxidation process was stopped
by the addition of EDTA (1 mglml).
MDA-LDL and MDA-HSA. Freshly-isolated LDL (2 mgfml) or
human serum albumin (2 mg/mI) were incubated for three hours
at 37°C with 0.5 M MDA, obtained by acid hydrolysis of MDA-
bisdimethyl-acetal. Unbound MDA was then removed by rapid
filtration through disposable desalting columns Econo-Pac 10 DG
(Bio-Rad). Under these conditions a large fraction of the s-amino
group in lysine residues was derivatized.
Evaluation of MDA- and HNE-adducts in modified proteins
The presence of MDA- and HNE-adducts in modified proteins
was detected using scanning fluorescence spectroscopy. Native or
modified LDL (1 mg/mI) or HSA (1 mg/ml) were resuspended in
10 m phosphate buffer and analyzed using a Perkin-Elmer LS-5B
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Table 3. Adduct formation upon incubation of native LDL and human
serum albumin with malondialdehyde
Conditions
Fluorescence arbitrary units
(400 nm excitation/470 nm emission)
Native LDL 22.1 1.8
+ 0.25 M malondialdehyde 93.4 5.6
Human serum albumin 2.1 0.3
+ 0.25 M malondialdehyde 107 7.7
Human serum albumin (1 mg/mI) and isolated human LDL (1 mg
mass/mi) were incubated without or with 0.25 M malondialdehyde for 3
hours at 37°C in 10 m phosphate buffer containing 1 mg/mI EDTA, pH
7.4. At the end of the incubation the samples were rapidly filtered through
desalting columns in order to remove unbound malondialdehyde and then
processed for fluorescence measurements as described in Methods.
Spectrofluorometer. The quantitation of the fluorescence inten-
sity at 360 nm excitation/430 nm emission was taken as an indirect
measure of the HNE-protein adduct and at 400 nm excitation/470
nm emission as an indirect measure of the MDA-protein adduct
[22].
Measure of anti-oxidized LDL and anti-MDA -modified LDL and
serum albumin autoantibodies
The quantitation of the different autoantibodies was performed
using an ELISA method. Disposable, 96-well polystyrene plates
(Corning) were employed. Antigens for this assay included native
LDL and underivatized human serum albumin (protected against
oxidation by EDTA), oxidized LDL (obtained after extensive
oxidation with 2 M CuSO4), and LDL and human serum
albumin, derivatized with MDA as described above. Each well was
coated with 10 .tg antigen in PBS for four hours. The remaining
binding sites were then blocked using 3% fetal bovine serum in
PBS (coating buffer) for two hours at 37°C.
In the present study, 1:11 dilution of plasma from each subject
was prepared and 220 .d were added in duplicate to wells coated
with native and modified proteins. After incubation at 37°C for
two hours, wells were decanted and washed four times before an
appropriate peroxidase-conjugated antibody specific for IgG or
1gM (diluted 1:2000) was added, After one hour incubation at
37°C and extensive washing, the peroxidase activity was developed
using phenylenediamine dihydrochioride and H202 as revealing
reagents. The absorbance was measured at 492 nm in an auto-
matic microplate reader. To calculate antibody titers the ratio
between the spectrophotometric readings of anti-modified and
anti-native antigen wells was used. Using this approach, the
spectrophotometric readings of anti-native antigen wells repre-
sented the corresponding blank of anti-modified antigen wells and
minimized the possible detection of false positive values due to
cross reactivity with both epitopes.
Measure of immune complexes containing oxidized LDL
The quantitation of immune complexes containing oxidized
LDL was performed using an ELISA method. Disposable, 96-well
polystyrene plates (Corning) were coated with an anti-copper-
oxidized human LDL serum developed in rabbit (diluted 1:2000;
provided by Prof. Hermann Esterbauer). After coating for four
hours at 37°C the remaining binding sites were blocked using 3%
fetal bovine serum in PBS (coating buffer) for two hours at 37°C.
The rationale behind this assay is that immobilized anti-oxLDL
Table 4. Formation of 4-OH-nonenal- and malondialdehyde-LDL
adducts in oxidized human low-density lipoproteins
Cu
Native oxidized
LDL LDL
Fluorescence wavelengths Fluorescence arbitrary Units
360 nm excitation/430 nm emission 12.5 2.3 35.4 5.4
(HNE-LDL adduct)
400 nm excitation/470 nm emission 22.1 1.8 38.8 4.4°
(MDA-LDL adduct)
Isolated human LDL (1 mg mass/mi) were incubated without or with 2
j.LM CuSO4 for 18 hours at 30°C in 10 m phosphate buffer, pH 7.4 and
then processed for fluorescence measurements as described in Methods.
Significantly different from native LDL, P < 0.01
antibodies (which coat the ELISA plate) bind both free and
conjugated oxidized LDL (immune complexes) present in diluted
plasma. The latter (oxidized LDL/anti-oxidized LDL complex)
can be subsequently detected using peroxidase-conjugated anti-
IgG or 1gM secondary antibody.
In the present study, 1:20 dilution of plasma from each subject
was prepared and 220 il were added in duplicate to wells coated
with native and modified proteins. After two hours incubation at
37°C, wells were decanted and washed four times before an
appropriate peroxidase-conjugated antibody specific for IgG or
1gM (diluted 1:2000) was added. After one hour incubation at
37°C and extensive washing, the peroxidase activity was developed
using phenylenediamine dihydrochloride and H202 as revealing
reagents. The absorbance was measured at 492 nm in an auto-
matic microplate reader. Absorbances higher that 1.000 (for a
1:20 dilution of the plasma) were considered positive.
Statistical analysis
All data were statistically analyzed with Student's t-test and
linear regression analysis using the Micro-Cal Origin and
CSS:Statistica programs for personal computers. Results are
expressed as mean SD.
Results
Antigen characterization: Formation of HNE-LDL and MDA-
LDL adducts during LDL oxidation
To obtain the formation of MDA-protein adducts, LDL or
human serum albumin, protected from spontaneous oxidation by
EDTA, were incubated with MDA. As shown in Table 3, this
treatment resulted in a substantial increase of the fluorescence
intensity at 400 nm excitation/470 nm emission, indicating the
occurrence of derivatization of the a-amino group in the lysine
residues with MDA. Using a similar protocol Palinski et al
obtained a derivatization of about 77% of the free amino groups
in LDL [23]. Moreover, long-term incubation of isolated human
LDL with CuSO4 caused a significant increase of the fluorescence
intensity at 360 nm excitation/430 nm emission and 400 nm
excitation/470 nm emission, indicating the derivatization of Apo
B100 with HNE and MDA occurring during the peroxidation of
LDL lipids triggered by Cu (Table 4), as previously reported
[23, 24]. These results indicate that: (i) incubation with MDA
actually generates MDA-derivatized LDL and HSA, and (ii) at
least two molecular epitopes (namely MDA-LDL and HNE-LDL)
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Table 5. Anti-oxidized LDL, anti-malondialdehyde-modified LDL and
albumin autoantibodies in plasma of CRF patients
Parameters
Control subjects(N = 72)
Uremic patients(N = 80)
Anti-oxLDL/natLDL IgO ratio
Anti-MDA-LDL/natLDL IgG ratio
Anti-MDA-HSAIHSA IgG ratio
Anti-oxLDLInatLDL 1gM ratio
Anti-MDA-LDL/natLDL 1gM ratio
Anti-MDA-HSA/HSA 1gM ratio
1.05 0.3
2.04 0.42
1.46 0.39
1.43 0.43
2.9 0.85
1.26 0.43
1.39 0.36a
3.05 074b
2.49 OS'
2.15 0.75"
5.55 1.79"
2.8 1.03"
a Statistically different from control subjects (P C 0.05)
"Statistically different from control subjects (P C 0.01)
are present in Cu -oxidized LDL used as antigens in the present
study.
Presence of autoantibodies against oxLDL, MDA-LDL and MDA-
HSA in uremic patients
As reported in Table 5, CRF patients had an antibody ratio
significantly higher than CS regarding anti-oxLDL IgG (1.39
0.36 vs. 1.05 0.3, P C 0.05) and 1gM (2.15 0.75 vs. 1.43 0.43,
P C 0.01), and anti-MDA-LDL IgG (3.05 0.74 vs. 2.04 0.42,
P C 0.01) and 1gM (5.55 1.79 vs. 2.9 0.85, P < 0.01). No
significant difference, however, was detected between patients on
peritoneal dialysis and hemodialysis, or, among the latter group,
between subgroups using different dialysis filter types. A further
analysis of the data obtained (Figs. 1 and 2) revealed a progressive
shift of the frequency distribution curve to the right, with a large
proportion of the antibody titer detected in CRF patients located
above the upper limit of the distribution obtained in control
subjects.
Competitive immunoassay studies have revealed that monoclo-
nal and polyclonal anti-MDA-LDL antibodies can cross react with
other substrates containing the MDA-lysine adduct [23]. For
these reasons we used MDA-modified human serum albumin as
antigen to detect the presence of autoantibodies in plasma of
CRF patients. As reported in Table 5, the anti-MDA-HSA
antibody titer was also higher in CRF patients than in CS (2.49
0.5 vs. 1.46 0.39, P C 0.01 for IgO and 2.80 1.03 vs. 1.26
0.43, P C 0.01 for 1gM). Again, no significant difference was
detected between CRF patients on peritoneal dialysis and hemo-
dialysis.
The presence of autoantibodies against two structurally-unre-
lated proteins, such as LDL and HSA, but which have been
derivatized with MDA suggests that the adduct MDA-lysine could
be the antigenic determinant. This conclusion is supported by the
demonstration of a strict correlation (r = 0.599, P C 0.001)
between the spectrophotometric readings of anti-MDA-LDL and
anti-MDA-HSA IgO (Fig. 3A). Values obtained in control sub-
jects were clustered in the lower left corner of the graph and were
encompassed by two lines that delineate four different fields.
Interestingly, most of the CRF patients were located in the upper
left field, indicating that the antibodies present in their plasma
reacted preferentially with MDA-LDL as compared to MDA-
HSA. A significant (r = 0.660, P C 0.001) correlation was also
detected for anti-MDA-LDL and anti-MDA-HSA 1gM (Fig. 3B).
However, in this case, the values for CRF patients were distrib-
uted in the two upper fields, indicating that, at least in 50% of the
patients, the antibodies detected recognized MDA-LDL and
Anti-MDA-LDL I9G autoantibody ratio
Fig. 1. Frequency distribution profile of anti-oxLDL and MDA-LDL IgG
autoantibodies in control subjects () and CRF patients (U).
MDA-HSA equally well. As reported above, the derivatization of
Apo B100 with MDA and other aldehydic products takes place
during in vitro oxidation of LDL. Thus, it can be conceivably
predicted that a correlation should also exist between anti-MDA-
LDL (or anti-MDA-HSA) and anti-oxLDL autoantibodies, and,
as reported in Figure 4, this was actually the case. A more detailed
analysis, however, revealed that, although the lgG detected in the
vast majority of patients recognized both oxLDL and MDA-LDL
(Fig. 4A), only a small fraction recognized both oxLDL and
MDA-HSA (Fig. 4B). On the other hand, the detected 1gM that
recognized oxLDL also recognized MDA-derivatized LDL and
HSA (Fig. 4C, D). Conversely, only a certain fraction of 1gM
reacting with MDA-derivatized LDL and HSA recognized oxLDL
equally well (Fig. 4C, D).
Specificity of oxidatively-modifled LDL as the molecule triggering
the immune response
The presence of autoantibodies reacting with both MDA-LDL
and MDA-HSA in plasma of CRF patients stimulates the ques-
tion of which molecule is triggering the immune reaction in vivo.
In other words, the production of autoantibodies could occur in
response to either specific LDL oxidation or non-specific oxida-
tive modifications of a variety of other molecules, including HSA.
A useful parameter to discriminate between these two possibilities
could be the ratio between the antibody titer against MDA-LDL
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Anti-MDA-LDL 1gM autoantibody ratio
Fig. 2. Frequency distribution profile of anti-oxLDL and MDA-LDL 1gM
autoantibodies in control subjects (dashed bars) and CRF patients (black
bars).
and MDA-HSA. As reported in Table 6, this value was higher
than one for both IgG and 1gM, indicating that MDA-LDL was
preferentially recognized by the antibodies detected in CRF
patients. A further analysis revealed a significant difference
between CRF patients on hemodialysis as compared to peritoneal
dialysis indicating that hemodialysis was, indeed, a more powerful
stimulus to specifically induce the production of anti-MDA-LDL
autoantibodies.
Detection of immune complexes containing oxLDL in plasma of
CRFpatients
Eight CRF patients had detectable levels of circulating immune
complexes containing oxLDL and IgG. Of the positive patients,
six were on hemodialysis (10.7%) and two were on peritoneal
dialysis (8.3%). On the other hand, immune complexes containing
1gM were undetectable in both groups of patients.
Correlation between anti-oxidatively-modified LDL autoantibodies
and clinical setting of CRFpatients
No correlation was found between anti-oxidatively-modified
LDL autoantibody titer (anti-oxLDL/natLDL IgG and 1gM ratio,
anti-MDA-LDL/natLDL IgG and 1gM ratio, anti-MDA-HSAJ
HSA IgG and 1gM ratio) and any of the following parameters:
presence of hypertension, diabetes mellitus, dislipidemia, obesity,
duration of the dialytic treatment. In addition, no correlation was
found with a score resulting from the clinical evaluation of the
severity and extent of atherosclerotic lesions. The clinical score
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derived from the presence of previous myocardial infarction,
angina pectoris, chronic ischemic cardiomyopathy, cerebral
chronic vasculopathy and peripheral artery occlusive diseases.
Furthermore, no correlation was detected with the concomitant
therapy (calcium-channel blocking drugs, cholesterol-lowering
drugs, beta-blockers, erythropoietin, inhibitors of the angiotensin
converting enzyme).
Discussion
The results obtained in this study demonstrate that: (i) autoan-
tibodies of the IgG and 1gM type against oxidatively-modified
LDL are produced by CRF patients on dialytic treatment, (ii) the
autoantibodies recognize other MDA-derivatized proteins and
(iii) immune complexes containing oxLDL are present in approx-
imately 10% of the patients. The detection of circulating autoan-
tibodies against oxidized LDL is considered to be a biological
signature of in vivo LDL oxidation. This implies that following
A
2500
2000
1500
1000
500
0
3000
2500
2000
1500
1000
(9C)
-J
-J
C
C)
-Ja
-J
9
C
0 200 400 600 800 1000 1200 1400
B
874 Maggi et a!: Anti-oxLDL autoantibodies in uremia
Table 6. Specificity of anti-oxidized LDL autoantibodies in plasma of
CRF patients on hemodialysis and peritoneal dialysis
Patients
Specific ratio
for IgG
Specific ratio
for 1gM
Total uremic patients (N = 80) 1.28 0.41 2.21 1.14
Patients on hemodialysis (N = 56) 1.34 0.43 2.41 1.22
Patients on peritoneal dialysis (N = 24) 1.12 0.29a 1.75 0.78a
a Statistically different from uremic patients on hemodialysis, P < 0.05
oxidative modifications of LDL occurring primarily in the suben-
dothelial space, antigenic epitopes would be generated and would
elicit an immune response. Among the various modifications of
apoprotein B100 structure occurring during peroxidation of LDL
lipids, the derivatization of the n-amino group of lysine with
malondialdehyde and 4-hydroxynonenal is able to stimulate the
production of specific antibodies [23-27}. Monoclonal antibodies
against oxidized LDL recognize modified apoproteins B100 in
early and advanced atherosclerotic lesions in rabbit and in hu-
mans [28—31]. Interestingly, in fatty streaks, rich in macrophages,
all iinmunostaining was located intracellularly and some immu-
nostained material was detected extracellularly only in advanced
lesions [32]. The detection of autoantibodies of the IgG and 1gM
type against MDA-modified LDL in CRF patients undergoing
dialysis strongly supports the view that this condition is associated
with an enhanced production of MDA-LDL occurring in vivo.
Since MDA represents one of the ultimate products of lipid
oxidation, it can conceivably be concluded that the occurrence of
this type of autoantibodies may be linked to an enhanced LDL
oxidation. Furthermore, the presence of autoantibodies against
MDA-modified HSA confirms that the immunogenic determinant
is probably the adduct MDA-lysine [23], but causes the non-trivial
question of which MDA-modified protein is the real immunogen
produced in vivo in CRF patients.
An increased level of plasma malondialdehyde, reflecting an
enhanced lipid peroxidation, has been reported in uremic patients
undergoing hemodialysis [18]. This has been claimed to result
from the bioincompatibility of the dialyzer membrane that would
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activate polymorphonuclear leukocytes, leading to the generation
of large amounts of oxygen activated species that would, in turn,
initiate peroxidation of polyunsaturated fatty acids [33]. Concom-
itantly, a decrease in intracellular and extracellular antioxidant
activity would render the target lipids more susceptible to the
oxidative attack [18, 34—36]. Under these conditions, a variety of
plasma proteins could interact with MDA with the formation of a
number of derivatized lysine residues eliciting an immune re-
sponse. In other terms, the specificity of MDA-derivatized LDL as
the immmune trigger would be at least questionable.
The assumption that in the presence of high amounts of MDA,
every derivatized protein could stimulate the production of au-
toantibodies reacting with the MDA-lysine adduct, seems, how-
ever, too simplistic. In a recent study we investigated the anti-
oxlDL autoantibody titer in three groups of patients with (a)
overt coronary atherosclerosis, (b) no clinical signs of atheroscle-
rosis but with an increased cardiovascular risk, and (c) no clinical
signs of atherosclerosis but with chronic alcoholic liver disease [8].
The latter group was characterized by a marked increase in
plasma peroxide and MDA levels and by the presence of circu-
lating MDA-HSA adducts [37]. The anti-oxLDL autoantibody
titer in this group was lower than that detected in atherosclerotic
patients and did not differ from that found in control subjects,
thus indicating that MDA overproduction was a condition not
sufficient to cause the generation of anti-oxLDL autoantibodies.
Another tempting way to escape this impasse has been em-
ployed in this work, using the ratio between anti-MDA-LDL/anti-
MDA-HSA antibody titer. This approach led to the demonstra-
tion that CRF patients had a ratio higher than 1 regarding both
IgG and 1gM autoantibodies, and that the ratio was lower in CRF
patients undergoing peritoneal dialysis as compared to hemodial-
ysis. This implies that: (i) MDA-LDL is the actual immunogen,
and (ii) it is preferentially generated in CRF patients on hemo-
dialysis. Support to these conclusions is given by previous reports
concerning an increased susceptibility to oxidation of LDL from
CRF patients, and the demonstration that short-term peritoneal
dialysis increased vitamin E concentration in LDL and amelio-
rated their resistance to oxidation [17].
The detection of anti-oxidatively modified LDL autoantibodies
in CRF patients, in addition to proving the occurrence of LDL
oxidation in vivo, questions the possible participation of this
immune response in the overall process of atherogenesis. The
autoimmune hypothesis of atherosclerosis was formulated some
30 years ago and it has been subsequently developed on the basis
of new immunological and clinical findings [38, 39]. A particular
aspect of this hypothesis predicts that immune complexes contain-
ing LDL would be efficiently taken up by macrophages forming
foam cells and early atherosclerotic lesions [40]. A significant
correlation has been, in fact, observed between the level of
circulating immune complexes and the degree of angiographi-
cally-demonstrated coronary stenosis [41]. Moreover, selective
removal of circulating immune complexes decreased the athero-
genic potential of the plasma and improved the clinical setting of
the atherosclerotic disease [42]. In order for immune complexes to
be formed, a generation of anti-LDL autoantibodies must occur,
preceded by a modification of the Apo B100 molecule to make it
immunogenic. Three major modifications occurring in vivo have
been reported to affect the structure and function of LDL:
glycation [43], desialylation [44] and oxidation [11]. Among them,
only oxidation has been compellingly demostrated to be able to
modi1' the antigenic properties of apoprotein B100 and to
stimulate the production of autoantibodies [23, 24]. The results
reported here indicate that immune complexes containing oxLDL
are present in the plasma of some CRF patients, although with no
significant correlation with the type and duration of dialytic
treatment and the degree and severity of the atherosclerotic
complications.
The detection of immune complexes containing oxLDL implies
the presence of oxLDL in the blood stream. Avogaro, Bittolo-Bon
and Cazzolato [45] have, indeed, reported that a small fraction of
circulating LDL (LDL—) has some of the biochemical features of
oxLDL. This view is apparently in contrast with a widely accepted
theory that the most important site for LDL oxidation is the
subendothelial space [10]. However, it is not possible to exclude
that oxLDL present in immune complexes may be generated from
the ulceration or rupture of complicated, advanced atheroscle-
rotic plaques, where oxLDL were detected in the extracellular
space [311.
The absence of a significant correlation between anti-oxidatively-
modified LDL and the degree and extension of the atherosclerotic
disease among CRF patients is not surprising. In fact it must be
kept in mind that atherosclerosis is a multifactorial disease and
LDL oxidation is just a part of it [1]. Moreover, the enhanced
LDL oxidation mirrored by high titers of anti-oxLDL autoanti-
bodies seems to be strictly associated with CRF [17, this study]. In
other words, it can be considered a factor independent from the
other classical risk factors for the progression of atherosclerosis,
such as hypertension, hypercholesterolemia, etc.
In conclusion, the findings reported in this work provide a
compelling demonstration that anti-oxidatively-modified LDL au-
toantibodies are present in plasma of CRF patients on dialytic
treatment. This demonstration, in addition to proving an en-
hanced LDL oxidation among uremic patients, envisages a possi-
ble participation of oxLDL-triggered immune reactions in the
progression of atherosclerosis among these patients. Long-term
longitudinal studies to evaluate this possibility are needed and are
currently in progress.
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Appendix 1. Abbreviations
CRF: chronic renal failure
CS: control subjects
HNE: 4-OH-nonenal
HSA: human serum albumin
LDL: low-density lipoprotein
MDA: rnalondialdehyde
oxLDL: oxidatively-modified LDL
oxLDLAb: autoantibodies against oxidatively-modified LDL
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